Clinical Trial

Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF)

Study acronym: IRONMETHFpEF
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to determine if the correction of functional iron deficiency by administering a single dose of intravenous iron (ferric derimaltose or Monoferric®) in participants with heart failure with preserved ejection fraction (HFpEF) will improve exercise capacity as measured by the change in peak oxygen uptake (peak VO2) from baseline to 12 weeks.
Protocol Amendment History 4 changes
critical Sponsor refiled this as active, not recruiting (was completed) 2026-08-14
critical Trial completed 2026-07-10
notable Primary completion pushed: 2026-03-31 -> 2026-06-25 2026-07-10
minor Completion moved earlier: 2026-07-31 -> 2026-06-25 2026-07-10
Trial Details
NCT Number NCT04945707
Lead Sponsor Massachusetts General Hospital
Collaborators: National Heart, Lung, and Blood Institute (NHLBI), Pharmacosmos A/S, National Institutes of Health (NIH)
Conditions Iron-deficiency, Heart Failure With Preserved Ejection Fraction
Enrollment 65 participants
Start Date 2021-11-26
Primary Completion 2026-06-25 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-08-13